Andrew B Singleton

List of Publications by Year
in descending order

75 papers	21,272 citations	57758 44 h-index	66911 78 g-index
88 all docs	88 docs citations	88 times ranked	24510 citing authors

#	Article	IF	Citations
1	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 267-282.	2.8	21
2	Heterozygous PRKN mutations are common but do not increase the risk of Parkinsonâ€™s disease. Brain, 2022, 145, 2077-2091.	7.6	26
3	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Movement Disorders, 2022, 37, 857-864.	3.9	15
4	Multi-modality machine learning predicting Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, 35.	5.3	44
5	Polygenic Resilience Modulates the Penetrance of Parkinson Disease Genetic Risk Factors. Annals of Neurology, 2022, 92, 270-278.	5.3	10
6	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	8.1	56
7	Genomeâ€Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. Movement Disorders, 2021, 36, 424-433.	3.9	101
8	The Parkinson's Disease <scp>DNA</scp> Variant Browser. Movement Disorders, 2021, 36, 1250-1258.	3.9	11
9	Assessing the relationship between monoallelic PRKN mutations and Parkinsonâ€™s risk. Human Molecular Genetics, 2021, 30, 78-86.	2.9	36
10	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
11	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
12	Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource. Movement Disorders, 2021, 36, 1795-1804.	3.9	60
13	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
14	A population scale analysis of rare SNCA variation in the UK Biobank. Neurobiology of Disease, 2021, 148, 105182.	4.4	5
15	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
16	The genetic architecture of Parkinson's disease. Lancet Neurology, The, 2020, 19, 170-178.	10.2	620
17	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurology, The, 2020, 19, 71-80.	10.2	94
18	Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149

#	Article	IF	Citations
19	Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinsonâ€™s disease. Journal of Medical Genetics, 2020, 57, 331-338.	3.2	36
20	LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Science Translational Medicine, 2020, 12, .	12.4	49
21	The Parkinson's Disease <scp>Genomeâ€Wide</scp> Association Study Locus Browser. Movement Disorders, 2020, 35, 2056-2067.	3.9	68
22	Parkinsonâ€™s disease determinants, prediction and geneâ€“environment interactions in the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1046-1054.	1.9	59
23	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. Movement Disorders, 2020, 35, 1999-2008.	3.9	104
24	Assessment of Genetic Association Between Parkinson Disease and Bipolar Disorder. JAMA Neurology, 2020, 77, 1034.	9.0	4
25	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Crossâ€Sectional Study. Movement Disorders, 2020, 35, 833-844.	3.9	48
26	Fineâ€Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Annals of Neurology, 2020, 87, 584-598.	5.3	39
27	Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. Neurobiology of Disease, 2020, 137, 104782.	4.4	241
28	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	3.9	57
29	Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease. Human Molecular Genetics, 2019, 28, 3244-3254.	2.9	56
30	The Parkinson's Disease Mendelian Randomization Research Portal. Movement Disorders, 2019, 34, 1864-1872.	3.9	50
31	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
32	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
33	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
34	Genome-wide estimates of heritability and genetic correlations in essential tremor. Parkinsonism and Related Disorders, 2019, 64, 262-267.	2.2	10
35	Parkinson's disease age at onset genomeâ€wide association study: Defining heritability, genetic loci, and Î±â€synuclein mechanisms. Movement Disorders, 2019, 34, 866-875.	3.9	258
36	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118

#	Article	IF	Citations
37	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
38	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. Movement Disorders, 2018, 33, 771-782.	3.9	136
39	Leucine rich repeat kinase knockout (LRRK KO) mouse model: Linking pathological hallmarks of inherited and sporadic Parkinson's disease. Movement Disorders, 2018, 33, 72-72.	3.9	2
40	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
41	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
42	The Parkinson's progression markers initiative (PPMI) â€“ establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 2018, 5, 1460-1477.	3.7	330
43	A comprehensive analysis of SNCAâ€•related genetic risk in sporadic parkinson disease. Annals of Neurology, 2018, 84, 117-129.	5.3	50
44	NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiology of Aging, 2017, 57, 247.e9-247.e13.	3.1	108
45	Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease. Movement Disorders, 2017, 32, 1164-1164.	3.9	2
46	A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nature Genetics, 2017, 49, 1511-1516.	21.4	944
47	Parkinson disease and clathrin coat dynamics at synapses, why not?. Movement Disorders, 2017, 32, 1163-1163.	3.9	4
48	Transcriptomic profiling of the human brain reveals that altered synaptic gene expression is associated with chronological aging. Scientific Reports, 2017, 7, 16890.	3.3	47
49	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.1	139
50	Juvenile onset Parkinsonism with â€œpure nigralâ€•degeneration and POLG1 mutation. Parkinsonism and Related Disorders, 2016, 30, 83-85.	2.2	9
51	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	3.1	78
52	CSF biomarkers associated with disease heterogeneity in early Parkinsonâ€™s disease: the Parkinsonâ€™s Progression Markers Initiative study. Acta Neuropathologica, 2016, 131, 935-949.	7.7	190
53	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. American Journal of Human Genetics, 2016, 98, 500-513.	6.2	333
54	Targeting Î±-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurology, The, 2015, 14, 855-866.	10.2	393

#	Article	IF	Citations
55	Genomeâ€wide association study of neocortical Lewyâ€related pathology. Annals of Clinical and Translational Neurology, 2015, 2, 920-931.	3.7	25
56	Head injury, potential interaction with genes, and risk for Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 292-296.	2.2	27
57	NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiology of Aging, 2015, 36, 1605.e7-1605.e12.	3.1	96
58	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurology, The, 2015, 14, 1002-1009.	10.2	179
59	Genome-Wide Analysis of the Heritability of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 1123.	9.0	69
60	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neuroscience, 2014, 17, 664-666.	14.8	398
61	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics, 2014, 46, 989-993.	21.4	1,685
62	A Genome-Wide Association Study of Depressive Symptoms. Biological Psychiatry, 2013, 73, 667-678.	1.3	149
63	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 2012, 21, 4996-5009.	2.9	176
64	Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. PLoS Genetics, 2012, 8, e1002548.	3.5	495
65	The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 2011, 95, 629-635.	5.7	1,278
66	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
67	Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in Human Brain. PLoS Genetics, 2010, 6, e1000952.	3.5	722
68	Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics, 2009, 41, 1308-1312.	21.4	1,745
69	Susceptibility genes in movement disorders. Movement Disorders, 2008, 23, 927-934.	3.9	2
70	DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurology, The, 2008, 7, 207-215.	10.2	202
71	Altered Î±-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. Trends in Neurosciences, 2005, 28, 416-421.	8.6	50
72	Analysis of an earlyâ€onset Parkinson's disease cohort for DJâ€1 mutations. Movement Disorders, 2004, 19, 796-800.	3.9	71

#	Article	IF	Citations
73	Parkinson's disease and dementia with Lewy bodies: a difference in dose?. Lancet, The, 2004, 364, 1105-1107.	13.7	80
74	X-linked recessive dystonia parkinsonism (XDP; Lubag; DYT3). Advances in Neurology, 2004, 94, 139-42.	0.8	3
75	Familiality in simple and complex disease. Clinical Autonomic Research, 2003, 13, 88-90.	2.5	1